In both ZVex- and G100–ZVex-treated mice, the ratio of tumor-specific CD8 T cells to regulatory T cells in the tumor was increased by a factor of more than 30 (Supplementary Fig. 5c). This evidence concerns the gene CD8A and neoplasm.